News

AGC Inc. Receives Best Acquisition Award for Adding the Former MolMed into AGC Biologics

News

(SEATTLE), May 19, 2021 -- AGC Biologics, a leading global Biopharmaceutical Contract Development and Manufacturing Organization (CDMO), announced their win of the M&A Award for Best Acquisition, Cross-Border into Italy, presented by KPMG, Fineurop Soditic, and others. This award is dedicated to showcasing the best of the Italian M&A market.

Oculis Selects AGC Biologics’ Heidelberg Facility to Manufacture OCS-02

Events

(SEATTLE), May 6, 2021 -- AGC Biologics, a leading global Biopharmaceutical Contract Development and Manufacturing Organization (CDMO), has announced its partnership with Oculis to manufacture OCS-02, a Phase II investigational drug targeting both Dry Eye Disease and Anterior Uveitis, at its Heidelberg facility.

Follow Us
Join us on LinkedIn Follow us on Twitter